Toward pecision-based prevention: trends in the burden of adverse effects of medical treatment in China based on GBD data and identification of high-risk elderly male groups

Read full text
Authors: LI Qiongqiong, Dan Ye
Cited by: 0

Abstract

Abstract Objective To analyze the status and trends of the burden of adverse effects of medical treatment (AEMT) in China from 1990 to 2023 using open data from the Global Burden of Disease (GBD) 2023. Methods Based on the GBD 2023 data, we extracted the number of incident cases, prevalent cases, disability-adjusted life years (DALYs), and deaths due to AEMT in China from 1990 to 2023. We also extracted age-standardized rates, including the age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), age-standardized DALYs rate (ASDR), and age-standardized mortality rate (ASMR). The annual percent change (APC), average annual percent change (AAPC), and their 95% confidence intervals (95% CI) for ASIR, ASPR, ASDR, and ASMR were calculated to analyze trends in the burden of AEMT in China. Epidemiological characteristics and differences in the AEMT burden among different age and sex groups in China were compared for the years 1990, 2020, and 2023. Results From 1990 to 2023, the number of incident cases, prevalent cases, DALYs, and deaths due to AEMT in China changed from 432 784 (95%UI:347 489 to 526 244), 33 087 (95%UI: 24 103 to 42 381), 686 404(95%UI:398 451 to 1 086 894), and 11 426(95%UI:7 233 to 17 456) to 342 349(95%UI: 279 429 to 423 443), 26 165(95%UI: 19 529 to 33 662), 121 245(95%UI: 90 707 to 155 623), and 3 337(95%UI: 2 494 to 4 212) in 2020, and further to 372 069 (95%UI: 303 152 to 464 618), 28 436 (95%UI: 21 029 to 36 643), 107 384(95%UI, 79 527 to 137 417), and 3 128 (95%UI: 2 305 to 3 985) in 2023. From 1990 to 2023, the AAPC values for ASIR, ASPR, ASDR, and ASMR were -0.994 8%(95%CI: -1.199 7% to -0.789 5%), -0.993 3%(95%CI: -1.202 2% to -0.783 9%), -5.968 4%(95%CI: -6.195 9% to -5.740 3%), and -5.432 2% (95%CI: -5.658 8% to -5.205 1%), respectively (P

Fields of Study & Subjects

Pharmacovigilance and Adverse Drug Reactions Patient Safety and Medication Errors Pharmaceutical Practices and Patient Outcomes

Publication details

Journal / source
DOAJ (DOAJ: Directory of Open Access Journals)
Publication date
1 February 2026
Language
ZH